Tag
NASDAQ: GMAB
- Genmab reports 75% first-line response in petosemtamab colorectal study
- Genmab and Incyte agree to colorectal cancer combination trial
- Zentalis Pharmaceuticals reports 15.8‑month survival in ovarian cancer subgroup
- Genmab A/S reports 51% lower progression or death risk in Phase 3 lymphoma trial
- Genmab A/S reports 45.9% Rina‑S response in ovarian cancer trial